ClinicalTrials.gg
TerminatedNCT03927911FUSIONUpdated Nov 9, 2021Results posted

Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries

A Phase 4 interventional study of EXPAREL and Bupivacaine and Standard of Care in Postoperative Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to protocol feasibility given the rapid evolution of medical practice for spinal procedure. Data from approximately 65 FUSION study subjects will be analyzed with the intent to create either a future study or registry for this patient population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Enrollment
58th of 93
65 · median 80
Started
2019
with 14 others
Phase 4
52 of 93
5 open now
Registered
56th of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 58th largest by enrollment, is one of 15 that started in 2019, is one of 52 in phase 4, and was the 56th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Primary Objective: The primary objective of this study is to compare postsurgical opioid consumption through 72 hours postsurgery in patients receiving local infiltration analgesia (LIA) with EXPAREL and bupivacaine HCl (EXPAREL group) with that of patients receiving standard of care (SOC) (control group) in adult subjects undergoing posterior lumbar spine surgeries where both groups are receiving a multimodal pain regimen.

Secondary Objectives: The secondary objectives of this study are to:

  1. Compare safety and effectiveness outcomes following LIA with EXPAREL and bupivacaine hydrochloride (HCl) versus SOC in adult subjects undergoing posterior lumbar spine surgeries through 72 hours, including time to first opioid and opioid-related adverse events (ORAEs).
  2. Compare health outcomes following LIA with EXPAREL and bupivacaine hydrochloride (HCl) versus SOC in adult subjects undergoing posterior lumbar spine surgeries, including discharge readiness, hospital (or other facility) length of stay (LOS), discharge disposition, hospital readmissions, and health service utilization.
Read the detailed description

This is a Phase 4, multicenter, prospective, active-controlled, real world, study in approximately 225 adult subjects undergoing posterior lumbar spine surgery under general anesthesia.

Subjects will be screened within 30 days prior to surgery; screening on the day of surgery will be allowed but is discouraged. If a subject can only be screened on the day of surgery, the informed consent process must still be started at least 24 hours prior to the conduct of any screening procedures that are not considered SOC at the institution and such procedures may not be performed until written informed consent is provided. All screening procedures that are not SOC must be performed and documented within the 30-day time window (inclusive of the day of surgery for those subjects who can only be screened on the day of surgery) as described here.

During the screening visit, subjects will be assessed for any past or present medical conditions that in the opinion of the investigator would preclude them from study participation. After the ICF is signed, the following information will be recorded and procedures done: medical history, surgical history, medication history, the subject's opioid use history will be recorded to calculate mean daily mg oral morphine equivalent dosing (MED PO) in the last 30 days, demographic and background information, height, weight and body mass index (BMI), a urine pregnancy test for women of childbearing potential, and the subject's current adverse experiences (AEs), if any.

Subjects will be asked questions and/or be asked to fill forms as part of the following assessments: Brief Pain Inventory - short form (BPI-sf), 5-item Opioid Compliance Checklist (OCC), Hospital Anxiety and Depression Scale (HADS), Survey of Pain Attitudes (SOPA), Numeric Rating Scale (NRS) ti assess pain and Opioid Related Symptom Distress Scale (ORSDS).

Based on the planned surgical procedure, subjects will be placed in one of three cohorts:

  • Cohort 1 - Open lumbar spinal fusion technique; ("open" cohort)
  • Cohort 2 - Minimally invasive tubular and/or percutaneous pedicle screw insertion for lumbar decompression with or without fusion;("tubular/percutaneous without midline incision" cohort)
  • Cohort 3 - Lumbar decompression surgery (LDS) without fusion (discectomy or laminectomy outpatient cohort)

The initial sample size in each study cohort (i.e., cohort 1, cohort 2 and cohort 3) is estimated at 75 subjects (50 subjects with EXPAREL and 25 subjects with Control group), for a total of 225 subjects in all three cohorts. Within each assigned cohort, subjects will be allocated in a 2:1 ratio to the EXPAREL (50 subjects) and Control group (25 subjects).

The following sequence will be followed for all cohorts: First, the subjects who meet eligibility criteria will be treated according to the institution's SOC. Their data will be collected prospectively. Next, at each investigational site, the administration of EXPAREL and bupivacaine HCl to the first 1 to 3 subjects in each cohort will be observed to ensure that the correct procedure for infiltration as described in the infiltration guide is being followed. If the infiltration was performed correctly, the subject will be included in the study. If the infiltration was performed incorrectly, the subject will continue in the study but will be removed from statistical analysis and will be replaced to ensure at least 50 evaluable EXPAREL patients are enrolled per cohort. If subjects are discontinued for other reasons, they will be replaced such that a total sample size of 75 fully evaluable subjects is obtained in each study cohort, with 50 in the EXPAREL group and 25 in the Control group.

03

Conditions studied

  • Postoperative Pain Management

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-75 years old at the time of screening.
  2. Primary surgical indication is related to spinal degenerative disease, including any of the following:

    1. Spinal stenosis
    2. Spondylolisthesis
    3. Radiculopathy/instability disc disorders
    4. Degenerative disc disease
  3. Medically cleared for elective spine surgery.
  4. Scheduled to undergo:

    1. Elective (i.e., not emergency)
    2. Lumbosacral (i.e., L1-S1)
    3. Posterior approach with posterior instrumentation
  5. Cohort 1 - Open only:

    Open or mini-open surgical technique with:

    1. 1-level (i.e., spanning 2 vertebrae) or 2-level (i.e., spanning 3 contiguous vertebrae)
    2. Primary fusion or revision fusion
    3. Open or mini-open surgical technique
  6. Cohort 2 - Tubular or percutaneous cohort only:

    1. 1-level (i.e., spanning 2 vertebrae) or 2-level (i.e., spanning 3 contiguous vertebrae)
    2. Primary fusion or revision fusion
    3. Tubular or percutaneous surgical technique
  7. Cohort 3 - Lumbar decompression without fusion outpatient cohort only:

    1. Radiculopathy
    2. Spinal stenosis
  8. Able to provide and adhere to all study assessments and visit schedule

Exclusion criteria

Exclusion Criteria:

  1. Serious spinal pathology determined by Investigator that might meaningfully affect postsurgical outcomes, including any of the following:

    1. Suspected cauda equina syndrome (e.g., bowel/bladder involvement)
    2. Infection
    3. Tumor
    4. Fracture
    5. Systemic inflammatory spondyloarthropathy
  2. to local anesthesia according to the clinical judgment of the Investigator and based on the EXPAREL label.
  3. Patients who most likely will require patient-controlled analgesia (PCA) pumps in EXPAREL group.
  4. Anterior surgical approaches, including any of the following:

    1. Anterior lumbar interbody fusion (ALIF)
    2. Oblique lumbar interbody fusion (OLIF)
    3. Anterior-posterior or 360º fusion
  5. Lateral surgical approaches, including any of the following:

    1. Extreme lateral interbody fusion (XLIF)
    2. Direct lateral interbody fusion (DLIF)
  6. High-dose presurgical opioid use:

    a) Mean daily intake greater than 100 mg mEq PO in the past 30 days

  7. Known allergy, , or contraindication to any of the following study medications:

    1. Bupivacaine
    2. EXPAREL
    3. Tylenol (acetaminophen)
    4. Robaxin
    5. 2 or more NSAIDs
    6. 2 or more gabapentinoids
    7. 2 or more rescue opioids (e.g., oxycodone, morphine, hydromorphone)
    8. 2 or more medications for postoperative nausea, vomiting, or pruritus (e.g., dexamethasone, ondansetron)
  8. History of severely impaired renal or hepatic function.
  9. Severe chronic pain that requires analgesic treatment, and in the opinion of the principal Investigator, is likely to meaningfully affect postsurgical outcomes.
  10. Subjects that have implanted spinal cord stimulator or intrathecal drug pump.
  11. Any neurologic or psychiatric disorder that might impact postsurgical pain or interfere with study assessments per Investigator discretion.
  12. in the last 2 years.
  13. History of misuse, abuse, or dependence on opioid analgesics, other prescription drugs, illicit drugs, or alcohol as defined in (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition). Dependence or chronic opioid use will be defined as use of more than 30 morphine equivalents per day during the prior 90 days.
  14. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
  15. \< 17 kg/m2 or >44 kg/m2 at screening
  16. Subjects receiving Worker's Compensation for disability or who are involved in other litigation related to the spine.
  17. Planned concurrent surgical procedure.
  18. Previous participation in an EXPAREL study.
  19. Administration of any drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.

In addition, the subject might be excluded from the study prior to study drug infiltration if one of the following criteria during the surgical procedure is met:

  1. Unable to place planned surgical instrumentation
  2. Poor fixation at the time of surgical instrumentation

In addition, the subject must be considered an early termination if one of the following criteria after the surgical procedure is met:

  1. An incision size >20 cm
  2. Autograft taken from a harvest site other than surgical site (i.e., iliac crest autograft)
  3. Intraoperative complications likely to meaningfully affect postsurgical outcomes, including any of the following:

    1. and prolonged (i.e., >24 hours) neurologic deficit (e.g., foot drop)
    2. Dural tear or suspected dural tear requiring bed rest (exception: subject will be allowed if the dural tear is fixed as per SOC of the institution during surgery)
    3. Extensive bleeding (i.e., >1,000 mL blood loss)
    4. Symptomatic epidural hematoma
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Active comparator
    Open or mini-open surgical technique cohort

    Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort

    Drug: EXPAREL and Bupivacaine · Drug: Standard of Care

  • Active comparator
    Tubular or Percutaneous cohort (Minimally Invasive Cohort)

    Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort

    Drug: EXPAREL and Bupivacaine · Drug: Standard of Care

  • Active comparator
    Lumbar decompression without fusion (Outpatient Cohort)

    Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort

    Drug: EXPAREL and Bupivacaine · Drug: Standard of Care

Interventions

  • DrugEXPAREL and Bupivacaine

    Drug page: Liposomal Bupivacaine

    Drug: EXPAREL and Bupivacaine HCl 0.5%

  • DrugStandard of Care

    Standard of Care

06

What researchers measure

Primary outcomes

  1. Post-surgical Opioid Consumption in mg MED PO (0-72 Hours)

    Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery

    Time frame: 0-72 hours

Secondary outcomes

  1. Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery

    Post-surgical opioid consumption in mg MED PO at 14 days after surgery

    Time frame: 0-14 days after surgery

  2. Time to First Opioid Rescue Through 72 Hours or Discharge.

    Time to first opioid rescue through 72 hours or discharge.

    Time frame: 0-72 hours

07

Results

Posted Nov 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control Group
Started017031332
Completed015011325
Not completed020207
Withdrew: Problems with ediary010104
Withdrew: Adverse event000001
Withdrew: Not treated -study terminated by sponsor010000
Withdrew: Surgery cancelled000101
Withdrew: Protocol violation000001

Outcome measures

PrimaryPost-surgical Opioid Consumption in mg MED PO (0-72 Hours)

Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery

Time frame:
0-72 hours
Reported as:
Mean · MED, mg
Post-surgical Opioid Consumption in mg MED PO (0-72 Hours)
MED, mgCohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control Group
Post-surgical Opioid Consumption in mg MED PO (0-72 Hours)—90.7 ± 96.91—56.8 ± 5.3051.6 ± 60.9883.6 ± 109.84
SecondaryPost-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery

Post-surgical opioid consumption in mg MED PO at 14 days after surgery

Time frame:
0-14 days after surgery
Reported as:
Mean · MED, mg
Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery
MED, mgCohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control Group
Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery—279 ± 330.66—330.8 ± 42.78158.4 ± 242.71187.7 ± 252.40
SecondaryTime to First Opioid Rescue Through 72 Hours or Discharge.

Time to first opioid rescue through 72 hours or discharge.

Time frame:
0-72 hours
Reported as:
Median · hours
Time to First Opioid Rescue Through 72 Hours or Discharge.
hoursCohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control Group
Time to First Opioid Rescue Through 72 Hours or Discharge.—0.82 (0.58 to 8.02)—0.36 (0.03 to 0.68)3.07 (0.60 to 25.10)0.95 (0.83 to 1.52)

Adverse events

Collected over AEs were collected from time of signing informed consent to Day 30 phone call.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1:Open or Mini-open Surgical Technique———
Cohort 1 Control Group0/16 (0%)0/16 (0%)6/16 (37.5%)
Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)———
Cohort 2 Control Group0/2 (0%)0/2 (0%)0/2 (0%)
Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)0/13 (0%)1/13 (7.7%)8/13 (61.5%)
Cohort 3 Control Group0/30 (0%)1/30 (3.3%)19/30 (63.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control Group
Cauda equina syndromeNervous system disorders————1/131/30
Lumbar Spinal StenosisMusculoskeletal and connective tissue disorders————0/131/30
Spinal epidural haematomaNervous system disorders————0/131/30
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control Group
SomnolenceNervous system disorders—0/16—0/20/139/30
ConstipationGastrointestinal disorders—2/16—0/22/137/30
Disturbance in attentionNervous system disorders—0/16—0/20/135/30
FatigueGeneral disorders—0/16—0/20/135/30
Stitch abcessInfections and infestations—0/16—0/22/130/30
NauseaGastrointestinal disorders—0/16—0/21/134/30
DizzinessNervous system disorders—0/16—0/21/133/30
DysuriaRenal and urinary disorders—0/16—0/20/133/30
Peripheral swellingGeneral disorders—0/16—0/21/130/30
Postoperative wound complicationInjury, poisoning and procedural complications—0/16—0/21/130/30

Baseline characteristics

Trial was terminated, not all arms had participants enrolled.

Age, Continuous
Age, Continuous(years)Cohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control GroupTotal
Mean—60.94 (47 to 75)—56 (53 to 60)52.38 (22 to 74)52.66 (21 to 72)55.495 (21 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control GroupTotal
Female080091128
Male090342137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control GroupTotal
Hispanic or Latino0000000
Not Hispanic or Latino01603122758
Unknown or Not Reported0100157
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control GroupTotal
American Indian or Alaska Native—0—0000
Asian—0—0000
Native Hawaiian or Other Pacific Islander—0—0000
Black or African American—1—0012
White—15—3122959
More than one race—0—0000
Unknown or Not Reported—1—0124
Region of Enrollment
Region of Enrollment(participants)Cohort 1:Open or Mini-open Surgical TechniqueCohort 1 Control GroupCohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)Cohort 2 Control GroupCohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)Cohort 3 Control GroupTotal
United States—17—3133265
08

Study locations

12 sites
  • Yale School of Medicine
    New Haven, Connecticut 06511, United States
  • Marcus Neuroscience Institute
    Boca Raton, Florida 33486, United States
  • University of Miami
    Miami, Florida 33136, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • The Orthopaedic Institute of Western Kentucky
    Paducah, Kentucky 42003, United States
  • Bronson Methodist Hospital
    Kalamazoo, Michigan 49007, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Carolina NeuroSurgery & Spine Associates, P.A.
    Charlotte, North Carolina 28204, United States
  • M3-Emerging Medical Research, LLC
    Durham, North Carolina 27704, United States
  • The Ohio State University
    Columbus, Ohio 43203, United States
  • Summit Spine Institute
    Portland, Oregon 97225, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Aug 2020, 12 months.

Results were first posted in Nov 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2019
First posted
Apr 25, 2019
StartActual
Jul 31, 2019
Primary completionActual
Aug 4, 2020
CompletionActual
Aug 4, 2020
Results first posted
Nov 9, 2021
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03927911
Responsible party
Sponsor
First posted
Apr 25, 2019
Start date
Jul 31, 2019
Primary completion
Aug 4, 2020
Completion
Aug 4, 2020
Results posted
Nov 9, 2021
Last update
Nov 9, 2021

Study contacts

Gary Nevins, DC
study director · Pacira Pharmaceuticals, Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion